Perspective announces first patient dosed with (212Pb)VMT-alpha-NET
Summary
Perspective Therapeutics announced that the first patient has been dosed with (212Pb)VMT-alpha-NET. The news signals progress in the company’s clinical pipeline rather than a commercial software product event. Because the company operates in life sciences, the item still fits an ISV-adjacent industry audience. The release does not indicate an immediate software procurement or partner evaluation need.
Classifications
industries
HealthTech
applications
Business Intelligence
AskAI Classifications
Labels
No AI classifications detected